Adjunctive Fasudil Use and Outcomes After Clazosentan Treatment for Aneurysmal Subarachnoid Hemorrhage: A Multicenter DCI Japan Registry Study
Journal of Clinical Medicine · 19.08.2026 · 15 (16) · 6424
DOI: 10.3390/jcm15166424 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 19.08.2026. Verfasst von Shingo Matsuda und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Hiroshima, Japan. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research, the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement, the Insight Research Ireland Centre for Data Analytics under grant agreement.
Abstract (Originalsprache)
Background/Objectives: Subarachnoid hemorrhage (SAH) is frequently complicated by cerebral vasospasm (VS). Clazosentan reduces VS, and fasudil hydrochloride hydrate (Fasudil) is widely used for VS prevention in Japan. However, the benefit of adding Fasudil to clazosentan remains unclear. We investigated whether adjunctive Fasudil was associated with VS-related and functional outcomes in clazosentan-treated aneurysmal SAH.
Methods
We retrospectively analyzed data from the multicenter “Database of Cohort Study for Outcome of SAH in Japan,” collected from 2020 to 2024. Patients with aneurysmal SAH who underwent surgical clipping or endovascular coiling within 4 days of onset and completed 14 days of clazosentan treatment were included. Outcomes were compared between clazosentan plus Fasudil and clazosentan alone. Multivariable logistic regression assessed factors associated with angiographic vasospasm (AVS), cerebral infarction, and poor functional outcome (modified Rankin Scale 3–6) at discharge and 6 months.
Results
Among 341 patients, 100 (29.3%) received adjunctive Fasudil and 241 (70.7%) clazosentan alone. AVS occurred in 58/329 (17.6%), cerebral infarction in 58/327 (17.7%), poor functional outcome at discharge in 142/341 (41.6%), and poor functional outcome at 6 months in 82/325 (25.2%). Adjunctive Fasudil was independently associated with higher odds of AVS (adjusted odds ratio [aOR] 2.41, 95% confidence interval [CI] 1.21–4.81), cerebral infarction (aOR 2.10, 95% CI 1.08–4.09), and poor 6-month outcome (aOR 2.88, 95% CI 1.08–7.71), but not with poor functional outcome at discharge (aOR 1.37, 95% CI 0.62–3.03).
Conclusions
In clazosentan-treated aneurysmal SAH, adjunctive Fasudil use was not associated with additional benefit and was associated with higher odds of AVS, cerebral infarction, and poor functional outcome at 6 months.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Hiroshima, Japan.
- Department of Neurosurgery, Shimane Prefectural Central Hospital, Izumo 693-8555, Shimane, Japan.
- Physical Education and Health Center, Nagaoka University of Technology, Nagaoka 940-2137, Niigata, Japan.
- Insight Research Ireland Centre for Data Analytics, School of Health and Human Performance, Dublin City University, D09 YT18 Dublin, Ireland.
- Sendai Headache and Neurology Clinic, Sendai 982-0014, Miyagi, Japan.
- Department of Neurosurgery, Japanese Red Cross Asahikawa Hospital, Asahikawa 070-0061, Hokkaido, Japan.
ORCID-Profile: Shingo Matsuda, Masahito Katsuki, Yasuhiko Matsumori, Daizo Ishii, Yoji Tanaka, Motohiro Morioka, Akihiro Hirayama, Ichiro Nakahara, Fusao Ikawa
Förderung
- Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research
- the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement
- the Insight Research Ireland Centre for Data Analytics under grant agreement
- European Union’s Horizon 2020 research and innovation programme
- Insight Research Ireland Centre for Data Analytics
Zitieren
APA
Matsuda, S., Katsuki, M., Inoue, Y., Hidaka, T., Matsumori, Y., Ishii, D., Takizawa, K., Tanaka, Y., Chin, M., Morioka, M., Kurita, H., Hirayama, A., Irie, K., Nakahara, I., Horie, N., Ikawa, F., & DCI Japan Study Group (2026). Adjunctive Fasudil Use and Outcomes After Clazosentan Treatment for Aneurysmal Subarachnoid Hemorrhage: A Multicenter DCI Japan Registry Study. Journal of Clinical Medicine, 15(16), 6424. https://doi.org/10.3390/jcm15166424
Vancouver
Matsuda S, Katsuki M, Inoue Y, Hidaka T, Matsumori Y, Ishii D, et al. Adjunctive Fasudil Use and Outcomes After Clazosentan Treatment for Aneurysmal Subarachnoid Hemorrhage: A Multicenter DCI Japan Registry Study. Journal of Clinical Medicine. 2026;15(16):6424. doi:10.3390/jcm15166424
BibTeX
@article{Matsuda2026,
author = {Matsuda, Shingo and Katsuki, Masahito and Inoue, Yusuke and Hidaka, Toshikazu and Matsumori, Yasuhiko and Ishii, Daizo and Takizawa, Katsumi and Tanaka, Yoji and Chin, Masaki and Morioka, Motohiro and Kurita, Hiroki and Hirayama, Akihiro and Irie, Koreaki and Nakahara, Ichiro and Horie, Nobutaka and Ikawa, Fusao and DCI Japan Study Group, DCI Japan Study Group},
title = {Adjunctive Fasudil Use and Outcomes After Clazosentan Treatment for Aneurysmal Subarachnoid Hemorrhage: A Multicenter DCI Japan Registry Study},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {16},
pages = {6424},
doi = {10.3390/jcm15166424}
}
EUVIMED